Mark M. Awad, MD, PhD, assistant professor of Medicine at Harvard Medical School and clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute, shares insights into a recent study, conducted in collaboration with Foundation Medicine, that looked at 60,000 patients with non-small cell lung cancer (NSCLC) with a subset of 1,387 patients with the MET exon 14 (METex14) mutations.

Learn more by clicking here.